Loading…
Prediction of Interindividual Variability in Pharmacokinetics for CYP3A4 Substrates in Humans
A method for predicting the interindividual variability of human exposure for CYP3A4 substrates using Monte Carlo simulation was developed based on relevant factors. The coefficient of variation (CV) values for CYP3A4 content in human liver microsomes, hepatic blood flow, liver volume and body weigh...
Saved in:
Published in: | DRUG METABOLISM AND PHARMACOKINETICS 2010-01, Vol.25 (4), p.367-378 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c612t-451e728021bc7abd51c859db404d164e718ea1fcea2bbc2623a43b0e6c4e73913 |
---|---|
cites | cdi_FETCH-LOGICAL-c612t-451e728021bc7abd51c859db404d164e718ea1fcea2bbc2623a43b0e6c4e73913 |
container_end_page | 378 |
container_issue | 4 |
container_start_page | 367 |
container_title | DRUG METABOLISM AND PHARMACOKINETICS |
container_volume | 25 |
creator | Kato, Motohiro Chiba, Koji Ito, Takashi Koue, Toshiko Sugiyama, Yuichi |
description | A method for predicting the interindividual variability of human exposure for CYP3A4 substrates using Monte Carlo simulation was developed based on relevant factors. The coefficient of variation (CV) values for CYP3A4 content in human liver microsomes, hepatic blood flow, liver volume and body weight, and the unbound blood fraction were collected from the published literature. The parallel tube and dispersion models were found to be appropriate mathematical models to describe the pharmacokinetics (PK). Simulation results using 33% as the CV for CYP3A4 content reflected reported CV values of the area under the curve (AUC) for 40 CYP3A4 substrates for both intravenous and oral administration. We also successfully predicted the clearance of midazolam in Japanese and in European American subjects. In all cases, the simulated mean and SD values reflected the reported values. Thus, the interindividual variability of the AUC of CYP3A4 substrates was predictable for both intravenous and oral administration. |
doi_str_mv | 10.2133/dmpk.DMPK-09-RG-038 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_754013016</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1347436715300446</els_id><sourcerecordid>754013016</sourcerecordid><originalsourceid>FETCH-LOGICAL-c612t-451e728021bc7abd51c859db404d164e718ea1fcea2bbc2623a43b0e6c4e73913</originalsourceid><addsrcrecordid>eNp9kE1PFTEUhidGI4j-AhMzO1eD_Zz2LlyQi1yIGG9QSFyYph9nYmGmvbYdEv69nVxg6aanad_znPZpmvcYHRNM6Sc37e6OT79tv3Zo1V1tOkTli-YQS4nqAUEv654y0THai4PmTc63CFHKGXndHBAkMcNcHja_twmct8XH0MahvQgFkg_O33s367G90clr40dfHlof2u0fnSZt450PULzN7RBTu_61pSes_TGbXJIukJfk-TzpkN82rwY9Znj3WI-a67MvP9fn3eX3zcX65LKzPSalYxyDIBIRbKzQxnFsJV85wxBzuGcgsASNBwuaGGNJT6hm1CDobb2jK0yPmo977i7FvzPkoiafLYyjDhDnrARnCFOE-5qk-6RNMecEg9olP-n0oDBSi1a1aFWLVoVW6mqjqtba9eGRP5sJ3HPPk8caONsHpsWmHmMYqyJ1G-cU6seVjXiCok3tqHMQIhyxWmSl96IuQnIhBacV9HkPgqrr3kNS2XoItmIT2KJc9P996T-SwqDI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>754013016</pqid></control><display><type>article</type><title>Prediction of Interindividual Variability in Pharmacokinetics for CYP3A4 Substrates in Humans</title><source>ScienceDirect Freedom Collection</source><source>Free Full-Text Journals in Chemistry</source><creator>Kato, Motohiro ; Chiba, Koji ; Ito, Takashi ; Koue, Toshiko ; Sugiyama, Yuichi</creator><creatorcontrib>Kato, Motohiro ; Chiba, Koji ; Ito, Takashi ; Koue, Toshiko ; Sugiyama, Yuichi ; Chugai Pharmaceutical Co ; The University of Tokyo ; Otsuka Pharmaceutical Co ; Daiichi Sankyo Co ; Ltd ; Keio University</creatorcontrib><description>A method for predicting the interindividual variability of human exposure for CYP3A4 substrates using Monte Carlo simulation was developed based on relevant factors. The coefficient of variation (CV) values for CYP3A4 content in human liver microsomes, hepatic blood flow, liver volume and body weight, and the unbound blood fraction were collected from the published literature. The parallel tube and dispersion models were found to be appropriate mathematical models to describe the pharmacokinetics (PK). Simulation results using 33% as the CV for CYP3A4 content reflected reported CV values of the area under the curve (AUC) for 40 CYP3A4 substrates for both intravenous and oral administration. We also successfully predicted the clearance of midazolam in Japanese and in European American subjects. In all cases, the simulated mean and SD values reflected the reported values. Thus, the interindividual variability of the AUC of CYP3A4 substrates was predictable for both intravenous and oral administration.</description><identifier>ISSN: 1347-4367</identifier><identifier>EISSN: 1880-0920</identifier><identifier>DOI: 10.2133/dmpk.DMPK-09-RG-038</identifier><identifier>PMID: 20814158</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Area Under Curve ; CYP3A4 ; Cytochrome P-450 CYP3A - physiology ; drug discovery ; Humans ; Interindividual variability ; Intestinal Mucosa - metabolism ; Liver - metabolism ; Metabolic Clearance Rate ; Midazolam - pharmacokinetics ; Monte Carlo Method ; Monte Carlo simulation ; Pharmacokinetics ; physiologically based pharmacokinetics ; prediction</subject><ispartof>DRUG METABOLISM AND PHARMACOKINETICS, 2010-01, Vol.25 (4), p.367-378</ispartof><rights>2010 The Japanese Society for the Study of Xenobiotics</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c612t-451e728021bc7abd51c859db404d164e718ea1fcea2bbc2623a43b0e6c4e73913</citedby><cites>FETCH-LOGICAL-c612t-451e728021bc7abd51c859db404d164e718ea1fcea2bbc2623a43b0e6c4e73913</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20814158$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kato, Motohiro</creatorcontrib><creatorcontrib>Chiba, Koji</creatorcontrib><creatorcontrib>Ito, Takashi</creatorcontrib><creatorcontrib>Koue, Toshiko</creatorcontrib><creatorcontrib>Sugiyama, Yuichi</creatorcontrib><creatorcontrib>Chugai Pharmaceutical Co</creatorcontrib><creatorcontrib>The University of Tokyo</creatorcontrib><creatorcontrib>Otsuka Pharmaceutical Co</creatorcontrib><creatorcontrib>Daiichi Sankyo Co</creatorcontrib><creatorcontrib>Ltd</creatorcontrib><creatorcontrib>Keio University</creatorcontrib><title>Prediction of Interindividual Variability in Pharmacokinetics for CYP3A4 Substrates in Humans</title><title>DRUG METABOLISM AND PHARMACOKINETICS</title><addtitle>Drug Metab Pharmacokinet</addtitle><description>A method for predicting the interindividual variability of human exposure for CYP3A4 substrates using Monte Carlo simulation was developed based on relevant factors. The coefficient of variation (CV) values for CYP3A4 content in human liver microsomes, hepatic blood flow, liver volume and body weight, and the unbound blood fraction were collected from the published literature. The parallel tube and dispersion models were found to be appropriate mathematical models to describe the pharmacokinetics (PK). Simulation results using 33% as the CV for CYP3A4 content reflected reported CV values of the area under the curve (AUC) for 40 CYP3A4 substrates for both intravenous and oral administration. We also successfully predicted the clearance of midazolam in Japanese and in European American subjects. In all cases, the simulated mean and SD values reflected the reported values. Thus, the interindividual variability of the AUC of CYP3A4 substrates was predictable for both intravenous and oral administration.</description><subject>Area Under Curve</subject><subject>CYP3A4</subject><subject>Cytochrome P-450 CYP3A - physiology</subject><subject>drug discovery</subject><subject>Humans</subject><subject>Interindividual variability</subject><subject>Intestinal Mucosa - metabolism</subject><subject>Liver - metabolism</subject><subject>Metabolic Clearance Rate</subject><subject>Midazolam - pharmacokinetics</subject><subject>Monte Carlo Method</subject><subject>Monte Carlo simulation</subject><subject>Pharmacokinetics</subject><subject>physiologically based pharmacokinetics</subject><subject>prediction</subject><issn>1347-4367</issn><issn>1880-0920</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNp9kE1PFTEUhidGI4j-AhMzO1eD_Zz2LlyQi1yIGG9QSFyYph9nYmGmvbYdEv69nVxg6aanad_znPZpmvcYHRNM6Sc37e6OT79tv3Zo1V1tOkTli-YQS4nqAUEv654y0THai4PmTc63CFHKGXndHBAkMcNcHja_twmct8XH0MahvQgFkg_O33s367G90clr40dfHlof2u0fnSZt450PULzN7RBTu_61pSes_TGbXJIukJfk-TzpkN82rwY9Znj3WI-a67MvP9fn3eX3zcX65LKzPSalYxyDIBIRbKzQxnFsJV85wxBzuGcgsASNBwuaGGNJT6hm1CDobb2jK0yPmo977i7FvzPkoiafLYyjDhDnrARnCFOE-5qk-6RNMecEg9olP-n0oDBSi1a1aFWLVoVW6mqjqtba9eGRP5sJ3HPPk8caONsHpsWmHmMYqyJ1G-cU6seVjXiCok3tqHMQIhyxWmSl96IuQnIhBacV9HkPgqrr3kNS2XoItmIT2KJc9P996T-SwqDI</recordid><startdate>20100101</startdate><enddate>20100101</enddate><creator>Kato, Motohiro</creator><creator>Chiba, Koji</creator><creator>Ito, Takashi</creator><creator>Koue, Toshiko</creator><creator>Sugiyama, Yuichi</creator><general>Elsevier Ltd</general><general>Japanese Society for the Study of Xenobiotics</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100101</creationdate><title>Prediction of Interindividual Variability in Pharmacokinetics for CYP3A4 Substrates in Humans</title><author>Kato, Motohiro ; Chiba, Koji ; Ito, Takashi ; Koue, Toshiko ; Sugiyama, Yuichi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c612t-451e728021bc7abd51c859db404d164e718ea1fcea2bbc2623a43b0e6c4e73913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Area Under Curve</topic><topic>CYP3A4</topic><topic>Cytochrome P-450 CYP3A - physiology</topic><topic>drug discovery</topic><topic>Humans</topic><topic>Interindividual variability</topic><topic>Intestinal Mucosa - metabolism</topic><topic>Liver - metabolism</topic><topic>Metabolic Clearance Rate</topic><topic>Midazolam - pharmacokinetics</topic><topic>Monte Carlo Method</topic><topic>Monte Carlo simulation</topic><topic>Pharmacokinetics</topic><topic>physiologically based pharmacokinetics</topic><topic>prediction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kato, Motohiro</creatorcontrib><creatorcontrib>Chiba, Koji</creatorcontrib><creatorcontrib>Ito, Takashi</creatorcontrib><creatorcontrib>Koue, Toshiko</creatorcontrib><creatorcontrib>Sugiyama, Yuichi</creatorcontrib><creatorcontrib>Chugai Pharmaceutical Co</creatorcontrib><creatorcontrib>The University of Tokyo</creatorcontrib><creatorcontrib>Otsuka Pharmaceutical Co</creatorcontrib><creatorcontrib>Daiichi Sankyo Co</creatorcontrib><creatorcontrib>Ltd</creatorcontrib><creatorcontrib>Keio University</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>DRUG METABOLISM AND PHARMACOKINETICS</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kato, Motohiro</au><au>Chiba, Koji</au><au>Ito, Takashi</au><au>Koue, Toshiko</au><au>Sugiyama, Yuichi</au><aucorp>Chugai Pharmaceutical Co</aucorp><aucorp>The University of Tokyo</aucorp><aucorp>Otsuka Pharmaceutical Co</aucorp><aucorp>Daiichi Sankyo Co</aucorp><aucorp>Ltd</aucorp><aucorp>Keio University</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prediction of Interindividual Variability in Pharmacokinetics for CYP3A4 Substrates in Humans</atitle><jtitle>DRUG METABOLISM AND PHARMACOKINETICS</jtitle><addtitle>Drug Metab Pharmacokinet</addtitle><date>2010-01-01</date><risdate>2010</risdate><volume>25</volume><issue>4</issue><spage>367</spage><epage>378</epage><pages>367-378</pages><issn>1347-4367</issn><eissn>1880-0920</eissn><abstract>A method for predicting the interindividual variability of human exposure for CYP3A4 substrates using Monte Carlo simulation was developed based on relevant factors. The coefficient of variation (CV) values for CYP3A4 content in human liver microsomes, hepatic blood flow, liver volume and body weight, and the unbound blood fraction were collected from the published literature. The parallel tube and dispersion models were found to be appropriate mathematical models to describe the pharmacokinetics (PK). Simulation results using 33% as the CV for CYP3A4 content reflected reported CV values of the area under the curve (AUC) for 40 CYP3A4 substrates for both intravenous and oral administration. We also successfully predicted the clearance of midazolam in Japanese and in European American subjects. In all cases, the simulated mean and SD values reflected the reported values. Thus, the interindividual variability of the AUC of CYP3A4 substrates was predictable for both intravenous and oral administration.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>20814158</pmid><doi>10.2133/dmpk.DMPK-09-RG-038</doi><tpages>12</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1347-4367 |
ispartof | DRUG METABOLISM AND PHARMACOKINETICS, 2010-01, Vol.25 (4), p.367-378 |
issn | 1347-4367 1880-0920 |
language | eng |
recordid | cdi_proquest_miscellaneous_754013016 |
source | ScienceDirect Freedom Collection; Free Full-Text Journals in Chemistry |
subjects | Area Under Curve CYP3A4 Cytochrome P-450 CYP3A - physiology drug discovery Humans Interindividual variability Intestinal Mucosa - metabolism Liver - metabolism Metabolic Clearance Rate Midazolam - pharmacokinetics Monte Carlo Method Monte Carlo simulation Pharmacokinetics physiologically based pharmacokinetics prediction |
title | Prediction of Interindividual Variability in Pharmacokinetics for CYP3A4 Substrates in Humans |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T04%3A55%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prediction%20of%20Interindividual%20Variability%20in%20Pharmacokinetics%20for%20CYP3A4%20Substrates%20in%20Humans&rft.jtitle=DRUG%20METABOLISM%20AND%20PHARMACOKINETICS&rft.au=Kato,%20Motohiro&rft.aucorp=Chugai%20Pharmaceutical%20Co&rft.date=2010-01-01&rft.volume=25&rft.issue=4&rft.spage=367&rft.epage=378&rft.pages=367-378&rft.issn=1347-4367&rft.eissn=1880-0920&rft_id=info:doi/10.2133/dmpk.DMPK-09-RG-038&rft_dat=%3Cproquest_cross%3E754013016%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c612t-451e728021bc7abd51c859db404d164e718ea1fcea2bbc2623a43b0e6c4e73913%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=754013016&rft_id=info:pmid/20814158&rfr_iscdi=true |